➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Moodys
Johnson and Johnson
Merck
Dow
Mallinckrodt
Medtronic

Last Updated: October 23, 2020

DrugPatentWatch Database Preview

Claims for Patent: 10,383,864

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 10,383,864
Title:Methods for treatment of Fabry disease
Abstract: Provided are in vitro and in vivo methods for determining whether a patient with Fabry disease will respond to treatment with a specific pharmacological chaperone.
Inventor(s): Lockhart; David J. (Emerald Hills, CA), Castelli; Jeff (New Hope, PA)
Assignee: Amicus Therapeutics, Inc. (Cranbury, NJ)
Application Number:15/974,217
Patent Claims: 1. A method for treatment of Fabry disease in a human patient in need thereof, the method comprising administering to the patient about 50 to about 250 mg of 1-deoxygalactonojirimycin or a salt thereof every other day.

2. The method of claim 1, wherein the 1-deoxygalactonojirimycin or salt thereof is administered as an oral dosage form.

3. The method of claim 2, wherein the oral dosage form comprises a tablet, a capsule or a solution.

4. The method of claim 1, wherein the patient does not eat food from about 2 hours before to about 2 hours after administering the 1-deoxygalactonojirimycin or salt thereof.

5. The method of claim 1, wherein the 1-deoxygalactonojirimycin or salt thereof enhances .alpha.-galactosidase A activity.

6. The method of claim 1, wherein the patient is male.

7. The method of claim 1, wherein the patient is female.

8. The method of claim 1, wherein the patient is administered about 50 to about 150 mg of the 1-deoxygalactonojirimycin or salt thereof every other day.

9. The method of claim 1, wherein the patient is administered about 150 to about 250 mg of the 1-deoxygalactonojirimycin or salt thereof every other day.

10. A method for treatment of Fabry disease in a human patient in need thereof, the method comprising administering to the patient about 50 to about 250 mg of migalastat hydrochloride every other day.

11. The method of claim 10, wherein the migalastat hydrochloride is administered as an oral dosage form.

12. The method of claim 11, wherein the oral dosage form comprises a tablet, a capsule or a solution.

13. The method of claim 10, wherein the patient does not eat food from about 2 hours before to about 2 hours after administering the migalastat hydrochloride.

14. The method of claim 10, wherein the migalastat hydrochloride enhances .alpha.-galactosidase A activity.

15. The method of claim 10, wherein the patient is male.

16. The method of claim 10, wherein the patient is female.

17. The method of claim 10, wherein the patient is administered about 50 to about 150 mg of the migalastat hydrochloride every other day.

18. The method of claim 10, wherein the patient is administered about 150 to about 250 mg of migalastat hydrochloride every other day.

19. A method for treatment of Fabry disease in a human patient in need thereof, the method comprising administering to the patient a therapeutically effective dose of 1-deoxygalactonojirimycin or a salt thereof every other day, wherein the patient does not eat food from about 2 hours before to about 2 hours after administering the 1-deoxygalactonojirimycin or salt thereof.

20. The method of claim 19, wherein the patient is administered about 150 mg of the 1-deoxygalactonojirimycin or salt thereof every other day.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Mallinckrodt
AstraZeneca
Johnson and Johnson
Harvard Business School
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.